Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.36 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | CASP7 | P55210 | 2/20 | 0.36 |
| ▸ | CASP6 | P55212 | 2/20 | 0.36 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4950109 | 1.00 | ATM (0.39) | ATMCYP1A2CASP1CASP3CASP7 | |
| SCHEMBL4951270 | 1.00 | ATM (0.39) | ATMCYP1A2CASP1CASP3CASP7 | |
| SCHEMBL4951359 | 0.87 | ATM (0.42) | ATMCYP1A2CTSKCAPN1CTSS | |
| SCHEMBL5087976 | 0.83 | ATM (0.39) | ATMCYP1A2CASP1CASP3CASP7 | |
| SCHEMBL5087983 | 0.83 | ATM (0.39) | ATMCYP1A2CASP1CASP3CASP7 | |
| SCHEMBL4951378 | 0.79 | HTR2A (0.34) | — | |
| SCHEMBL3962356 | 0.78 | ATM (0.43) | ATMCTSKCTSLCTSSELANE | |
| SCHEMBL4948402 | 0.78 | CYP1A2 (0.37) | ATMCYP1A2CASP1CASP3CASP7 | |
| SCHEMBL4953959 | 0.78 | CYP1A2 (0.37) | ATMCYP1A2CASP1CASP3CASP7 | |
| SCHEMBL14277715 | 0.77 | ATM (0.38) | ATMCYP1A2CTSKCAPN1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425572-B2 | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma | ALCON, INC. (CH) | 2008-09-16 | — | — | US | disclosed |
| US-20060122251-A1 | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma | ALCON, INC. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122251-A1 | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma | CYP11B2, CYP11B1, PDE3A | ATM 3304/4885CYP1A2 157/4885CASP1 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.